Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Boan Biotech Nears Denosumab Registration After Phase III Enrollment Completion
Biosimilar Developer Is Nearing The Finish Line As Key Patents Are Set To Expire In 2025
26 Jan 2024
•
By
Urtė Fultinavičiūtė
Boan Biotech’s denosumab biosimilar BA6101 is already approved in China • Source: Shutterstock
More from Biosimilars
More from Products